Patient-reported Outcome Measurements on the Tolerance of Magnetic Resonance Imaging-guided Radiation Therapy

Cureus. 2018 Feb 27;10(2):e2236. doi: 10.7759/cureus.2236.

Abstract

Purpose Magnetic resonance imaging-guided radiation therapy (MRgRT) requires patient positioning within the MR bore and prolonged MR imaging during delivery, both of which are new in radiation oncology. Patient tolerance of MRgRT was prospectively evaluated using patient-reported outcome questionnaires (PRO-Q). Methods Our MRgRT procedure involves daily high-resolution MR scanning, limited re-contouring, daily plan re-optimization, quality assurance (QA), and gated delivery. Patients with claustrophobia are excluded. Mean fraction duration was 45 and 60 minutes for stereotactic treatments during free-breathing and breath-hold, respectively. Patient-controlled video-feedback was used for breath-hold delivery. PRO-Qs collected in the first 150 patients treated included questions on MR-related complaints and also evaluated aspects of active participation. Results Almost one-third of patients (29%) scored at least one PRO-Q item on MR-related complaints as 'moderate' or 'very much', with noise, feeling cold, and paresthesia being the most frequently scored in this way. Considerable anxiety was reported by 5%, but no medication was required for this in any patient. Patient participation in video feedback for breath-hold delivery was appreciated by the majority of patients, all of whom completed the procedure. Only 5% of patients considered treatment duration to be unacceptably long. Conclusion Despite the lengthy MRgRT procedure, outcomes of PRO-Q indicate that it was well-tolerated by patients.

Keywords: adaptive; implementation; mrgrt; patient tolerance; pro-q; smart; stereotactic.

Grants and funding

Dr. Bruynzeel reports speaker grants and travel fee from ViewRay, Inc. Dr. Slotman reports grants and personal fees from Varian Medical Systems outside the submitted work, speaker grants and travel fee from ViewRay, Inc., and grants and personal fees from BrainLab AG, outside the submitted work. Dr. Haasbeek reports speaker grants from Varian medical systems outside the submitted work Dr. Senan reports grants from Varian Medical Systems and personal fees from Eli Lilly, AstraZeneca and Merck-Sharp-Dohme, outside the submitted work. Dr. Lagerwaard reports speaker grants and travel fee from ViewRay, Inc.